Tipoline vs. semaglutide: Why is the “dual agonist” mechanism stronger?

1. Telboride vs. Smegglutide: Both are GLP-1 receptor agonists, but what are the differences in their effects?

In the field of weight loss drugs, semaglutide ( trade name Wegovy/Ozempic ) was once considered one of the most effective GLP-1 receptor agonists, capable of reducing appetite, lowering calorie intake, and slowing gastric emptying , thereby helping obese and diabetic patients control their weight. However, Tirzepatide ( Mounjaro ), approved by the FDA in 2022 , completely changed this landscape.

The key difference lies in the " dual agonist " mechanism of telpotetide —a dual agonist of GLP-1 and GIP receptors . Compared to smegglutide, which is a single GLP-1 receptor agonist, telpotetide can further enhance insulin sensitivity and promote fat breakdown while controlling appetite, thus resulting in a stronger weight loss effect.

 

2. GLP-1 receptor agonists ( Semaglutide ): Main function

Smegglutinin ( Wegovy/Ozempic ) , as a GLP-1 receptor agonist, primarily aids in weight loss through the following mechanisms:

✔ Suppresses appetite : Acts on the appetite center in the brain, making people feel fuller and reducing calorie intake.

✔ Delaying gastric emptying : Food stays in the stomach longer, prolonging the feeling of fullness and reducing the frequency of eating.

✔ Promotes insulin secretion and lowers blood sugar : Reduces glucagon release, helps the body metabolize blood sugar better, and reduces fat accumulation.

However, the drawback of smegglutide is that it has a weak direct effect on fat metabolism, which can easily lead to a plateau in weight loss , and some people may experience a rebound after stopping the medication .

 

3. The " dual agonist " mechanism of telpoeptide: How does GLP-1 + GIP work more effectively?

In addition to acting on the GLP-1 receptor, telpolide can also activate the GIP (glucose-dependent insulinotropic peptide) receptor , making it more effective in metabolic regulation.

✔ GLP-1 controls appetite + GIP promotes fat metabolism , working together to accelerate weight loss.

✔ It enhances insulin sensitivity , reduces insulin resistance, and stabilizes blood glucose metabolism, making it suitable for people with prediabetes or metabolic disorders.

✔ GIP receptor agonism can improve energy metabolism and promote fat breakdown more directly , rather than simply relying on reducing food intake.

✔ GIP can also reduce gastrointestinal side effects , so telpolide is better tolerated and has relatively milder side effects than smegglutide.

📌 Key data comparison ( SURMOUNT vs. STEP study):

drug	Maximum weight loss effect	Clinical trials	Target audience
Mounjaro (a type of peptide)	22.5% weight loss	SURMOUNT-1 study ( 2022 )	Obese, prediabetic, type 2 diabetic patients
Smegglutinin ( Wegovy )	16.9% weight loss	STEP-1 study ( 2021 )	Obese patients with prediabetes

Studies have shown that telpolide has a weight loss effect that is about 5.6% higher than that of smegglutide , and it is more advantageous for overweight or diabetic patients.

 

4. Telborpeptide vs. Smeglucopeptide: Which one is more suitable for you?

✅ If you want stronger weight loss results and to see weight loss faster, choose telpoeptide .

✅ If you have poor tolerance to GLP-1 drugs (such as Wegovy ) and are prone to nausea and vomiting, telpolide may be a better option .

✅ If your primary goal is to control blood sugar but you don't have high expectations for weight loss, Smegglutide can also meet your needs .

✅ If you have insulin resistance or prediabetes, the GIP effect of telpolide can better improve metabolism .

📌 Summarize:

🔹 The " dual agonist " mechanism of telpokines makes it more effective than smegglutinin in weight loss and metabolic improvement.

🔹 It is suitable for people who need more significant weight loss, have prediabetes or diabetes, and have poor tolerance to GLP-1 .

🔹 Clinical data confirms that telpoeptide not only controls appetite but also directly promotes fat breakdown, making weight loss more efficient and less prone to rebound.